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MaBACKGROUND Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients
with reduced ejection fraction. Its interplay with systolic blood pressure (SBP) is not known.
OBJECTIVES The goal of this study was to evaluate the interplay of SBP and the effects of empagliflozin in EMPEROR-
Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction).
METHODS Study patients (N ¼ 3,730) were randomly assigned to groups according to SBP at baseline (<110 mm Hg,
n ¼ 928; 110-130 mm Hg, n ¼ 1,755; >130 mm Hg, n ¼ 1,047). This study explored the influence of SBP on the effects of
empagliflozin on cardiovascular death or HF hospitalization (primary outcome), as well as on total HF hospitalizations, rate
of decline in estimated glomerular filtration rate, renal outcomes, and empagliflozin’s effects and significance on SBP.
RESULTS Over a median of 16 months considering only patients receiving placebo, baseline SBP and the risk of car-
diovascular death or hospitalization for HF (P trend ¼ 0.0015) were inversely related. Corrected for placebo, a slight
early increase was observed in SBP at <110 mm Hg, no change at 110-130 mm Hg, and a slight reduction at >130 mm Hg.
These between-group differences were of borderline significance (P for interaction trend ¼ 0.05-0.10) after 4 and
12 weeks but were not significant later. SBP at baseline did not influence the effect of empagliflozin to reduce the risk of
HF events or renal endpoints. When treated with empagliflozin, patients with SBP <110 mm Hg did not have an increased
rate of symptomatic hypotension.
CONCLUSIONS Empagliflozin was effective and safe, with no meaningful interaction between SBP and the effects of
empagliflozin in the EMPEROR-Reduced trial. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With
Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977) (J Am Coll Cardiol 2021;78:1337–1348) © 2021 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2021.07.049
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ABBR EV I A T I ON S
AND ACRONYMS
DBP = diastolic blood pressure
eGFR = estimated glomerular
filtration rate
SBP = systolic blood pressure
SGLT2 = sodium-glucose
cotransporter-2
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1338S odium-glucose cotransporter-2 (SGLT-2) inhibitors have been shown toreduce cardiovascular death and heart
failure hospitalization in patients with dia-
betes (1-3) and with heart failure with
reduced ejection fraction with and without
diabetes (4-5). In addition, these drugs
reduce systolic blood pressure (SBP) in pa-
tients with diabetes and hypertension (6,7).Because of fears that these heart failure medications
may lower blood pressure, they are often not pre-
scribed or are used at low doses, especially in patients
with a low SBP at the start of treatment (8,9). There is
an inverse relationship between SBP and the risk of
cardiovascular death and hospitalization for heart
failure in patients who have heart failure and a
reduced ejection fraction (10). Thus, patients with
the lowest SBP are at the highest risk but may be least
likely to receive effective treatments.
Accordingly, we evaluated the interplay of baseline
SBP and the effects of empagliflozin in patients
enrolled in EMPEROR-Reduced (Empagliflozin
Outcome Trial in Patients With Chronic Heart Failure
With Reduced Ejection Fraction), with a particular
emphasis on patients with the lowest SBP.SEE PAGE 1349METHODS
STUDY DESIGN. The design and results of the
EMPEROR-Reduced trial have been published previ-
ously (5,11). The ethics committees of each of the
participating institutions approved the protocol, and
all patients gave written informed consent. The regis-
tration identifier at ClinicalTrials.gov is NCT03057977.
STUDY PATIENTS AND PROCEDURES. Patients were
screened and those fulfilling eligibility criteria were
randomized double-blind in a 1:1 fashion to receive
placebo or empagliflozin 10 mg daily in addition to
their usual therapy for heart failure. Patients with or
without diabetes were enrolled. During follow-up,
all accompanying treatments could be altered or
initiated according to the changes in the clinical
status of the patients at the clinical discretion of
the investigator.
At the screening visit, after the patient had rested
quietly in the seated position for 5 minutes, 3 attended
blood pressure measurements were recorded, and
the mean of these 3 blood pressure values was used
to determine eligibility. Blood pressure was recorded
at every subsequent visit by using a standard
manometer with an appropriate size cuff at the same
arm in a sitting position after 5 minutes of rest.Patients were assessed at study visits for major
outcomes, vital signs, estimated glomerular filtration
rate (eGFR) according to the Chronic Kidney Disease
Epidemiology Collaboration equation, adverse
events, and changes in medications or clinical status
that reflected changes in the course of heart failure.
All randomized individuals were followed up for the
occurrence of pre-specified outcomes for the entire
duration of the trial regardless of whether the study
participants had taken the study medication or were
adherent with the study procedures according to the
intention-to-treat principle. At the end of double-
blind therapy, treatment with the study medications
was stopped, and patients underwent a follow-up
visit, including assessment of eGFR 23 to 45 days
later unconfounded by the presence of the study
medication.
TRIAL OUTCOMES. The primary endpoint of the
composite of adjudicated cardiovascular death or
hospitalization for heart failure was analyzed as time-
to-first event. The first secondary endpoint was the
occurrence of all adjudicated hospitalizations for heart
failure, including first and recurrent events. The sec-
ond secondary endpoint was the analysis of the slope
of the change in eGFR during double-blind treatment.
We also analyzed the change in eGFR from baseline to
the off-treatment values 23 to 45 days after discon-
tinuation of double-blind treatment. In addition, we
evaluated a renal composite endpoint, defined as the
need for chronic dialysis or renal transplant or a $40%
sustained decrease in eGFR or a sustained eGFR
<15 mL/min/1.73 m2 (if the baseline eGFR was $30
mL/min/1.73m2) or<10mL/min/1.73m2 (if the baseline
eGFR was <30 mL/min/1.73 m2).
SBP ANALYSES. Patients were grouped according to
their baseline SBP: <110 mm Hg, 110-130 mm Hg, and
>130 mm Hg. We evaluated the risk of a serious heart
failure and renal event in these groups in patients
receiving placebo, and we compared the effects of
empagliflozin versus placebo on efficacy variables in
these SBP categories. Furthermore, to understand the
influence of post-randomization changes in SBP in
mediating the effects of empagliflozin, the treatment
effects of empagliflozin were studied by using time-
updated SBP as a covariate. The influence of base-
line SBP on the occurrence of hypotension and
symptomatic hypotension was examined in the pla-
cebo and empagliflozin groups.
STATISTICAL ANALYSES. The effect of empagliflozin
compared with placebo on the time-to-first event
analyses was examined by using Cox proportional
hazards regression models with prespecified cova-
riates of age, sex, geographical region, diabetes









(n ¼ 1,047) P Value
Age, y 64.9  11.4 66.9  11.1 68.4  10.3 <0.0001
Female 196 (21.1) 433 (24.7) 264 (25.2) 0.0392
Race <0.0001
White 585 (63.0) 1251 (71.3) 793 (75.7)
Black 77 (8.3) 119 (6.8) 61 (5.8)
Asian 212 (22.8) 295 (16.8) 165 (15.8)
Other, including mixed races 35 (3.8) 61 (3.5) 18 (1.7)
Missing 19 (2.0) 29 (1.7) 10 (1.0)
Region <0.0001
North America 136 (14.7) 200 (11.4) 89 (8.5)
Latin America 321 (34.6) 625 (35.6) 340 (32.5)
Europe 260 (28.0) 639 (36.4) 454 (43.4)
Asia 176 (19.0) 193 (11.0) 124 (11.8)
Other 35 (3.8) 98 (5.6) 40 (3.8)
NYHA functional class 0.1437
II 680 (73.3) 1,329 (75.7) 791 (75.5)
III 243 (26.2) 421 (24.0) 246 (23.5)
IV 5 (0.5) 5 (0.3) 10 (1.0)
Body mass index, kg/m2 26.6  5.0 28.0  5.3 28.8  5.7 <0.0001
Heart rate, beats/min 71.0  11.9 71.1  11.6 71.8  11.8 0.1059
SBP, mm Hg 104.0  3.4 119.4  6.4 142.3  9.0 NA
DBP, mm Hg 66.6  7.7 73.2  9.0 81.4  11.1 <0.0001
Left ventricular ejection fraction, % 26.1  6.3 27.3  5.9 28.9  5.6 <0.0001
NT-proBNP, pg/mL 2,098.0 (1,235.5-3,905.5) 1,804.0 (1,074.0, 3,347.0) 1,851.0 (1,079.0, 3,244.0) <0.0001a
Medical history
Diabetes 412 (44.4) 879 (50.1) 565 (54.0) <0.0001
Hospitalization for heart failure in last 12 mo 339 (36.5) 522 (29.7) 290 (27.7) <0.0001
Atrial fibrillationb 350 (37.7) 642 (36.6) 377 (36.0) 0.3737
Hypertension 543 (58.5) 1,240 (70.7) 915 (87.4) <0.0001
eGFR
Mean, mL/min/1.73 m2 62.2  22.2 62.2  21.4 61.5  21.4 0.4330
eGFR <60 mL/min/1.73 m2 468 (50.4) 826 (47.1) 505 (48.2) 0.3677
Device therapy
Implantable cardioverter-defibrillatorc 344 (37.1) 557 (31.7) 270 (25.8) <0.0001
Cardiac resynchronization therapyd 133 (14.3) 212 (12.1) 97 (9.3) 0.0005
Heart failure medication
ACE inhibitors/ARBs/ARNi 800 (86.2) 1,549 (88.3) 944 (90.2) 0.0064
ACE inhibitors/ARBse 566 (61.0) 1,214 (69.2) 820 (78.3) <0.0001
ARNi 237 (25.5) 353 (20.1) 137 (13.1) <0.0001
Mineralocorticoid receptor antagonist 715 (77.0) 1,271 (72.4) 675 (64.5) <0.0001
Beta-blocker 880 (94.8) 1,661 (94.6) 992 (94.7) 0.9450
Values are n, mean  SD, n (%), or median (interquartile range). aBased on log-transformed results. bDefined as atrial fibrillation reported in any electrocardiogram before
treatment intake or history of atrial fibrillation reported in medical history. cImplantable cardioverter-defibrillator with or without cardiac resynchronization therapy. dCardiac
resynchronization therapy with or without a defibrillator. eExcluding valsartan when taken with sacubitril because sacubitril/valsartan is shown as an angiotensin receptor
blocker þ neprilysin inhibitor (ARNi).
ACE ¼ angiotensin-converting enzyme; ARBs ¼ angiotensin receptor blockers; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular filtration rate;
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; SBP ¼ systolic blood pressure.
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1339status at baseline, left ventricular ejection fraction,
and eGFR at baseline. The interaction between
(continuous) SBP and treatment group on the occur-
rence of the prespecified outcomes was tested by
using a treatment-by-SBP interaction term (testing for
a linear trend assuming ordered SBP categories). Thefirst secondary outcome of total (first and recurrent)
heart failure hospitalizations was evaluated with the
use of the joint frailty model that accounted for
informative censoring because of cardiovascular
death. Changes in SBP and diastolic blood pressure
(DBP) were analyzed in a mixed model with repeated
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SBP <110 mm Hg
SBP 110-130 mm Hg
SBP >130 mm Hg
Placebo
Adjusted mean change in systolic blood pressure (SBP) (A) or diastolic blood pressure (DBP) (B) (ordinate) from baseline (BL) to 124 weeks of
follow-up and placebo-corrected change in SBP (C) and DBP (D) from BL according to SBP at BL in patients treated with empagliflozin (Empa)
(solid lines) or placebo (dashed lines). CI ¼ confidence interval.
Continued on the next page
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1340measures. Between-group differences in the slope of
change in eGFR were analyzed by using a random
intercept random slope model using on-treatment
data. The slope, the joint frailty, and the mixed
model with repeated measures models included the
same covariates as the Cox model.
All analyses were performed by using SAS version
9.4 (SAS Institute, Inc). All P values reported are
2-sided, and P < 0.05 was considered as statistically
significant in all cases. No adjustments for multiple
testing were made from the exploratory nature of the
study.
DATA-SHARING STATEMENT. Data will be made
available upon request in adherence with trans-
parency conventions in medical research and through
requests to the executive committee. The executive
committee of EMPEROR-Reduced has developed a
comprehensive analysis plan and numerousprespecified analyses, which will be presented in
future scientific meetings and publications. At a later
time point, the full database will be made available in
adherence with the transparency policy of
the sponsor.
RESULTS
PATIENT CHARACTERISTICS. A total of 3,730 pa-
tients were randomly assigned to receive either
empagliflozin (n ¼ 1,863, 10 mg once daily) or placebo
(n ¼ 1,867) (Supplemental Figure 1). Table 1 presents
the baseline characteristics of patients in the 3 base-
line SBP categories. Those with lower SBP had a
greater severity of heart failure, as evidenced by a
lower ejection fraction, higher N-terminal pro–B-type
natriuretic peptide plasma concentrations, and a
higher likelihood of having experienced a heart
FIGURE 1 Continued
Diastolic Blood Pressure Change From BLB
Empagliflozin
SBP <110 mm Hg
SBP 110-130 mm Hg
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1341failure hospitalization in the last 12 months. Patients
with lower SBP were more likely to be treated with a
neprilysin inhibitor or have received an implanted
cardioverter-defibrillator and/or cardiac resynchro-
nization therapy device.
ASSOCIATION OF BLOOD PRESSURE WITH OUTCOMES.
The relationship of baseline SBP to the severity of
heart failure was further investigated by calculating
incidence rates for major endpoints in patients
receiving placebo. The incidence rate per 100 patient
years of follow-up for the primary endpoint
increased from 16.5 in patients with SBP >130 mm Hg
to 20.8 in patients with SBP of 110-130 mm Hg, and
to 26.3 in patients with SBP <110 mm Hg
(P trend ¼ 0.0015). The event rate per 100 patient
years of follow-up for total hospitalizations for heart
failure increased from 17.9 in patients with SBP
>130 mm Hg to 22.0 in patients with SBP of 110-
130 mm Hg and to 28.1 in patients with
SBP <110 mm Hg (P trend ¼ 0.0075).EFFECT OF EMPAGLIFLOZIN ON BLOOD PRESSURE.
The time course of SBP and DBP in the 2 treatment
groups according to baseline SBP categories is shown
in Figure 1A (SBP) and Figure 1B (DBP). When cor-
rected for placebo, we observed a slight early increase
in blood pressure in the <110 mm Hg group, no
change in the 110-130 mm Hg group, and a slight
reduction in the >130 mm Hg group. These between-
group differences were of borderline significance (P
for interaction trend ¼ 0.05-0.10) after 4 and 12 weeks
but were not significant at later time points
(Figures 1C and 1D).
SAFETY ASSESSMENTS. The incidence of symptom-
atic hypotension in the placebo group increased from
2.9 per 100 patient years of follow-up in patients with
SBP >130 mm Hg, to 4.0 in those with SBP 110-
130 mm Hg, and to 8.2 in patients with
SBP <110 mm Hg (Table 2). A similar pattern was
observed with hypotension. Treatment with empa-
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TABLE 2 Adverse Events According to Baseline SBP













n (%) IR/100 n (%) IR/100 n (%) IR/100 n (%) IR/100 n (%) IR/100 n (%) IR/100
Hypotensiona 62 (12.7) 11.8 58 (13.2) 12.4 66 (7.5) 6.6 88 (10.0) 8.6 35 (7.0) 5.9 30 (5.5) 4.6
Symptomatic hypotensionb 44 (9.0) 8.2 35 (8.0) 7.3 41 (4.7) 4.0 51 (5.8) 4.9 18 (3.6) 2.9 20 (3.6) 3.0
aBased on pre-selected adverse events. bInvestigator defined.
IR/100 ¼ incidence rate per 100 patient years; SBP ¼ systolic blood pressure.
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1343EFFECT OF EMPAGLIFLOZIN ON EFFICACY OUTCOMES.
The cumulative incidence functions of the primary
outcome (cardiovascular death or heart failure hospi-
talization) according to baseline SBP are shown in
Supplemental Figure 2. The relative risk reduction of
the primary outcome by empagliflozin was similar
across all SBP groups (P for interaction trend ¼ 0.83)
(Figure 2). When we investigated the treatment effects
from week 4 onward using SBP as a time-updated co-
variate, changes in SBP did not influence the effect of
empagliflozin on the primary endpoint (P for interac-
tion trend ¼ 0.43) (Supplemental Figure 3). SBP also
did not influence the magnitude of the risk reduction
produced by empagliflozin on total (first and recurrent)
hospitalizations for heart failure (P for interac-
tion trend ¼ 0.96).
Empagliflozin attenuated the slope of eGFR decline
similarly in all SBP categories (P for interaction
trend ¼ 0.68) (Figure 3A). Because the eGFR slope
could be influenced by the early eGFR changes on
empagliflozin but not on placebo, we evaluated the
eGFR change from baseline to the off-treatment
values at 23 to 45 days after discontinuation of ran-
domized treatments. There were no differences in the
treatment effect of empagliflozin in the SBP groups on
the eGFR change from baseline to off-treatment (P for
interaction trend ¼ 0.63) (Table 3). The effect of SBP
on the ability of empagliflozin to reduce the risk of
the renal composite was somewhat greater in patients
with SBP <110 mm Hg, but the P for interaction trend
was borderline significant (P ¼ 0.088) (Figure 3B), and
this analysis is based on sparse events.
DISCUSSION
We show an inverse relationship between SBP and the
risk of major cardiovascular outcomes in patients with
heart failure with reduced ejection fraction in the
EMPEROR-Reduced trial. Empagliflozin reduced the
risk of the primary outcome independently of baseline
SBP and SBP during the trial. Moreover, empagliflozin
reduced the number of total hospitalizations forheart failure, slowed eGFR decline, and reduced the
risk of a composite renal outcome consistently across
baseline SBP categories. Empagliflozin had only minor
effects on SBP and did not produce hypotension
or symptomatic hypotension, even in the patients
with the lowest baseline SBP (ie, <110 mm Hg).
Our finding that low baseline SBP is accompanied
by increased risk of serious heart failure outcomes
have previously been reported in several registries
(12) and trials such as PARADIGM-HF (13) and DAPA-
HF (Dapagliflozin and Prevention of Adverse Out-
comes in Heart Failure) (14) involving patients with
chronic heart failure. Progression of renal function
decline according to SBP with a nadir of 120 to
130 mm Hg has been observed in hypertension (15) as
well as in secondary prevention (16). However, we
found that renal function declined by w2 mL/
min/1.73 m2 per year on placebo irrespective of blood
pressure.
Empagliflozin reduced the risk of heart failure
outcomes independently of baseline SBP and SBP
during the trial. DAPA-HF assessed the effects of
dapagliflozin on heart failure outcomes and mortality
across 4 baseline SBP categories and adjusted for
updated mean SBP, and found results similar to ours
(14). We extend the findings from DAPA-HF by also
reporting renal effects according to SBP: baseline SBP
did not influence the reduction in renal function
decline by empagliflozin. Moreover, we observed a
consistent reduction in renal composite events across
baseline SBP. The effects of empagliflozin on the eGFR
slope, on the change in eGFR from baseline to off-
treatment, and the renal composite endpoints were
concordant and were not different between the SBP
subgroups. In prespecified analyses, it was already
shown that consistent effects on cardiorenal out-
comes in EMPEROR-Reduced were observed in pa-
tients with or without chronic kidney disease (eGFR
>60 mL/min/1.73 m2 and eGFR #60 mL/min/1.73 m2)
(17) and with or without diabetes (18). Here, we extend
these results by showing that SBP is not an effect
modifier for the cardiorenal effects of empagliflozin.
FIGURE 2 Treatment Effects According to Baseline SBP
Primary Outcome
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Incidence Rate per 100
Patient Years (95% CI)
30100 20



















Event Rates per 100
Patient Years
30100 20








Hazard Ratio (95% CI)
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Hazard ratios (HRs) (left), incidence rate per 100 patient years (middle), and HRs modeled as a continuous variable (right) for empagliflozin compared with placebo
according to baseline SBP for the primary outcome (composite of heart failure hospitalization or cardiovascular death) (A) and first and recurrent heart failure
hospitalization (B). IR ¼ incidence rate per 100 patient years; other abbreviations as in Figure 1.
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SBP <110 mm Hg
0.28 (0.10-0.75)
SBP 110-130 mm Hg
0.48 (0.23-0.99)
SBP >130 mm Hg
0.72 (0.35-1.49)
HR (95% CI)
Overall P for interaction trend
test = 0.088
Overall P for interaction trend
test = 0.68
1.51.00.50.0
SBP <110 mm Hg
1.85 (0.55-3.15)
SBP 110-130 mm Hg
1.79 (0.87-2.71)
SBP >130 mm Hg
1.56 (0.39-2.74)
Slope Difference (95% CI) by SBP Category
eGFR Change from Baseline Slope





Effect of empagliflozin compared with placebo on slope of change in estimated glomerular filtration rate (eGFR) (adjusted mean differences, mL/min/1.73 m2/year)
(left) and mean eGFR declines (right) (A) and the effect of empagliflozin compared with placebo on the risk of the composite renal outcomes (chronic dialysis, renal
transplant, 40% sustained decrease in eGFR or a sustained eGFR <15 mL/min/1.73 m2 [if baseline eGFR $30 mL/min/1.73 m2] or <10 mL/min/1.73 m2 [if baseline eGFR
<30 mL/min/1.73 m2]) (left) and incidence rates (right) (B). eGFR was calculated by using the Chronic Kidney Disease Epidemiology Collaboration equation. Ab-
breviations as in Figures 1 and 2.
TABLE 3 Change in eGFR From Baseline to Off-Treatment
SBP Group
Adjusted Change From
Baseline, Mean  SE Adjusted Mean (95% CI)
Treatment Comparison
At Follow-UpPlacebo Empagliflozin P Value
<110 mm Hg –4.4  1.1 –1.6  1.1 2.8 (–0.2 to 5.9) 0.0690
110-130 mm Hg –4.1  0.8 0.2  0.8 4.3 (2.1 to 6.5) 0.0001
>130 mm Hg –4.3  1.0 –2.1  0.9 2.1 (–0.5 to 4.8) 0.1112
P for interaction ¼ 0.63. Based on analysis of covariance with the following factors: baseline eGFR (according to
the Chronic Kidney Disease Epidemiology Collaboration equation) (continuous), age (continuous), region, sex, left
ventricular ejection fraction (categorical), baseline diabetes status, baseline SBP (categorical), treatment, and
baseline SBP*treatment interaction.
Abbreviations as in Table 1.
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patients with eGFR as low as 20 mL/min/1.73 m2 and
SBP as low as 100 mm Hg at baseline, thus involving
subgroups of more vulnerable patients. Similar
consistent reductions in renal events across SBP cat-
egories were already reported with canagliflozin in
patients with type 2 diabetes and chronic kidney dis-
ease in the CREDENCE (Canagliflozin and Renal
Events in Diabetes and Nephropathy Clinical Evalua-
tion) trial (19), but the lowest SBP category included in
those analyses was <130 mm Hg. Thus, we extend the
evidence for the use of SGLT2 inhibitors to patients
CENTRAL ILLUSTRATION Effect of Empagliflozin on Blood Pressure and Outcomes
Böhm, M. et al. J Am Coll Cardiol. 2021;78(13):1337–1348.
Placebo-corrected effect of empagliflozin on systolic blood pressure (SBP) according to baseline SBP (top), effect of empagliflozin on the primary outcome over the
spectrum of baseline SBP (middle), and effect of empagliflozin and placebo on decline of estimated glomerular filtration rate according to baseline SBP (bottom).
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1347with heart failure and reduced ejection fraction with
SBP <110 mm Hg, showing a benefit also in terms of a
reduction in serious adverse renal events.
In patients receiving placebo, we observed a slight
initial increase of SBP in the low SBP group and a
slight initial decline of SBP in patients with high SBP
at baseline, followed by stabilization in both groups.
This phenomenon has been shown previously in
heart failure trials (13,20-23) and may suggest
regression to the mean. However, it is noteworthy
that, during the first 4 to 12 weeks, empagliflozin
produced a slight increase in SBP in patients with a
SBP <110 mm Hg and a slight decrease in SBP in those
with a SBP >130 mm Hg (P for interaction
trend ¼ 0.06-0.07), with little change in SBP there-
after. Changes in SBP postrandomization did not in-
fluence the effect of empagliflozin on the primary
endpoint, suggesting that empagliflozin does not
produce its benefits on heart failure events through
an effect to reduce SBP. One might speculate that the
slight increase on empagliflozin compared with pla-
cebo could reflect an improvement of the heart failure
syndrome.
We observed that baseline SBP did not influence
the magnitude of the effect of empagliflozin to reduce
the risk of cardiovascular death or hospitalization for
heart failure. The hazard ratio in patients with
SBP <110 mm Hg was 0.78, similar to the effect seen
in the overall trial (0.75). However, because patients
with SBP <110 mm Hg represent a high-risk subgroup,
the absolute risk reduction with empagliflozin in pa-
tients with SBP <110 mm Hg tended to be greater than
in patients with SBP >130 mm Hg. Because patients
with SBP <110 mm Hg did not experience a decline in
SBP or an increased risk of hypotension or symp-
tomatic hypotension with empagliflozin, the benefit-
to-risk relationship for empagliflozin would seem to
be particularly favorable in patients with
SBP <110 mm Hg. These observations are relevant, as
physicians are often reluctant to initiate treatment
with outcome-modifying drugs in patients with heart
failure whose SBP is low (24).
STUDY LIMITATIONS. The major limitation of our
analysis is that the results are confined to those pa-
tients who did not meet exclusion criteria such as an
eGFR <20 mL/min/1.73 m2, symptomatic hypoten-
sion, or an SBP <100 mm Hg, as these patients were
not included in the EMPEROR-Reduced trial.
CONCLUSIONS
We confirmed in our analysis that patients with heart
failure with reduced ejection fraction and low SBP
(ie, <110 mm Hg) had the highest risk of heart failureoutcomes. Empagliflozin reduced the risk of heart
failure and renal outcomes independently of baseline
SBP. Patients in the low SBP group tolerated empa-
gliflozin treatment well and experienced no decline in
SBP and no increased rates of symptomatic hypo-
tension (Central Illustration).
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In patients with heart failure
and reduced left ventricular ejection fraction, empagli-
flozin reduces major adverse cardiovascular outcomes and
preserves renal function independently of SBP.
TRANSLATIONAL OUTLOOK: Additional studies are
required to elucidate the role of empagliflozin in high-risk
patients with heart failure and reduced ejection fraction.
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